Systemic Lupus Erythematosus

Clinical Snapshot

Systemic lupus erythematosus (SLE) is a chronic, relapsing-remitting autoimmune disease in which loss of immune tolerance to nuclear self-antigens drives autoantibody production and immune-complex-mediated inflammation across multiple organ systems.^[1] SLE is best understood as a spectrum: some patients have mild, clinically stable disease limited to skin and joints, while others develop severe, potentially life- or organ-threatening involvement of the kidneys, central nervous system, or blood. SLE also carries a substantially increased burden of comorbidity — cardiovascular disease, infection, and osteoporosis are major drivers of morbidity and mortality independent of lupus activity itself. There is no single diagnostic test; the diagnosis rests on a combination of characteristic clinical features, autoantibodies, and — when renal or other organ involvement is suspected — biopsy. Management layers onto every patient in the same order: hydroxychloroquine as background therapy regardless of severity, corticosteroids to control acute flares, and organ- and severity-matched immunosuppression (conventional agents, calcineurin inhibitors, or biologics) to induce and maintain remission while minimizing cumulative corticosteroid exposure.^[1]

Recognize the Condition

SLE has a fluctuating course of relapses and remissions, and its multisystem presentation is why diagnosis can be delayed or missed — no single symptom or organ pattern is unique to lupus. The organ domains below are not mutually exclusive; most patients accumulate manifestations from more than one over time.

Organ systems involved in SLE

Mucocutaneous

Acute cutaneous lupus (malar/"butterfly" rash sparing the nasolabial folds, often photosensitive), subacute cutaneous lupus (annular or psoriasiform, strongly photosensitive, frequently anti-Ro/SSA positive), chronic cutaneous (discoid) lupus (scarring, disc-shaped plaques), nonscarring alopecia, and typically painless oral or nasal ulcers.

Musculoskeletal

Synovitis in 2 or more joints with at least 30 minutes of morning stiffness — typically a symmetric, nonerosive, small-joint polyarthritis — and myalgia.

Serositis

Pleuritis (pleuritic chest pain, pleural effusion) and pericarditis (chest pain, pericardial friction rub, pericardial effusion).

Renal

Lupus nephritis is frequently clinically silent — detected through proteinuria, an active urinary sediment, or a rising creatinine on routine screening labs rather than through symptoms; hypertension and edema emerge with more advanced disease.

Hematologic

Autoimmune hemolytic anemia, leukopenia or lymphopenia, and thrombocytopenia.

Neuropsychiatric

Headache, cognitive dysfunction, mood disorder, seizure, psychosis, peripheral neuropathy, and cerebrovascular disease — the last particularly with concurrent antiphospholipid antibodies.

Vascular and constitutional

Raynaud phenomenon, livedo reticularis, cutaneous vasculitis, fatigue, and low-grade fever.

Risk Factors

Female sex, particularly during reproductive years — the age of peak disease onset.
Family history of SLE or another autoimmune disease.
Genetic factors, including complement deficiencies (e.g., C1q, C4) and certain HLA associations.
Ultraviolet light exposure — can trigger both cutaneous and systemic flares.
Cigarette smoking — worsens cutaneous damage accrual and reduces the effectiveness of antimalarial therapy.
Certain medications capable of triggering drug-induced lupus (see Assessment & Diagnosis for the causative-drug list and how it differs from idiopathic SLE).
Epstein-Barr virus and other environmental or infectious exposures implicated as disease triggers.
Hormonal factors, including estrogen exposure.

Red Flags & Refer

Any of the following needs urgent escalation beyond routine flare management — do not manage these as an outpatient flare with an empiric corticosteroid increase alone.

New or worsening signs of lupus nephritis — new proteinuria, hematuria, an active urinary sediment, rising creatinine, new hypertension, or new edema — refer urgently for nephrology assessment and renal biopsy; this is frequently asymptomatic and found only on labs.
CNS lupus — new seizure, psychosis, a stroke-like presentation, transverse myelitis, or a severe headache with new neurologic signs — emergency neurology/rheumatology assessment.
Severe cytopenias — severe autoimmune hemolytic anemia, severe thrombocytopenia with bleeding, or agranulocytosis — urgent hematology/rheumatology referral.
Catastrophic antiphospholipid syndrome — rapid, multi-organ thrombosis evolving over days in a patient with antiphospholipid antibodies — a medical emergency requiring immediate hospitalization and specialist-directed combination therapy.
Fever or any sign of serious infection in a patient on immunosuppression — treat as infection until proven otherwise; fever cannot be reliably distinguished from a flare on clinical grounds alone.
New or significantly worsening disease activity in pregnancy, or a pregnant patient with high-risk serology (anti-Ro/SSA, anti-La/SSB, or antiphospholipid antibodies) — refer to a high-risk multidisciplinary obstetric team.
Suspected macrophage activation syndrome — a rare but life-threatening hyperinflammatory complication of SLE presenting with persistent fever, cytopenias, markedly elevated ferritin, and hepatosplenomegaly — emergency hematology/rheumatology assessment.

Assessment & Diagnosis

Differentiating idiopathic SLE from drug-induced lupus

Distinguishing these matters because management is different — drug-induced lupus resolves after stopping the causative agent and does not need the immunosuppressive escalation used for idiopathic SLE.

Feature	Idiopathic SLE	Drug-induced lupus
Typical onset	Gradual, any age, predominantly young women	Weeks to months after starting an implicated drug; more common in older adults of either sex
Course after removing the trigger	Not applicable — chronic, relapsing-remitting	Resolves within weeks of stopping the drug, though autoantibody serology may take up to a year to normalize
Antinuclear antibody (ANA)	Positive	Positive (essentially universal)
Anti-histone antibody	Can be present	Present in most cases, though also seen in a substantial minority of idiopathic SLE
Anti-dsDNA / anti-Sm	Characteristically present	Typically absent
Renal or CNS involvement	Can occur	Rare
Typical causative drugs	Not applicable	Procainamide, hydralazine, quinidine, isoniazid, chlorpromazine, minocycline, terbinafine, and tumour necrosis factor-alpha inhibitors

A related but distinct phenomenon is drug-induced subacute cutaneous lupus, mediated by anti-Ro/SSA and anti-La/SSB antibodies rather than anti-histone antibodies — implicated drugs include calcium channel blockers, ACE inhibitors, hydrochlorothiazide, leflunomide, interferons, and terbinafine.

History

Assess overall health status, quality of life, pregnancy history and current pregnancy plans, a complete medication review (screening for the causative drugs above), and vaccination record.

Physical examination

Skin and oral mucosa for the cutaneous findings described in Recognize the Condition.
Joints for synovitis in 2 or more joints with at least 30 minutes of morning stiffness.
Imaging (chest x-ray, CT, ECG) when pleural effusion, pericardial effusion, or acute pericarditis is suspected.

Laboratory investigations

CBC to identify cytopenias (anemia, leukopenia, thrombocytopenia).
Creatinine, albumin, and urinalysis to screen for kidney involvement; quantify urine protein (spot protein-to-creatinine ratio) and pursue renal biopsy when indicated.
Autoantibody panel and tissue biopsy as indicated to support the diagnosis (see table below).
Anti-dsDNA — tracks with disease activity, kidney involvement, serositis, and hematologic manifestations, and is used to help monitor the clinical course over time.
C3 and C4 complement levels — characteristically low during active disease.
Anti-Ro/SSA and anti-La/SSB — particularly relevant when pregnancy is being considered or is present.
Antiphospholipid antibodies — when there is an unexplained clot or pregnancy complication (see Special Populations for the antiphospholipid syndrome pathway).

Autoantibodies used in SLE evaluation

Antibody	Clinical significance
Antinuclear antibody (ANA)	Highly sensitive screening test but low specificity — also positive in Sjögren syndrome, systemic sclerosis, and other conditions; a negative ANA makes SLE unlikely, but a positive ANA alone does not confirm it.
Anti-double-stranded DNA (anti-dsDNA)	Highly specific; correlates with disease activity, kidney involvement, serositis, and hematologic manifestations — used to help monitor the clinical course.
Anti-Smith (anti-Sm)	Highly specific for SLE.
Antiphospholipid antibodies (anticardiolipin, lupus anticoagulant, anti-beta-2-glycoprotein I)	May indicate antiphospholipid syndrome — assess thrombosis and pregnancy-loss history (see Special Populations).
Anti-Ro/SSA	Linked to photosensitive rash, dry eyes, and neonatal lupus/congenital heart block — test before or during pregnancy.
Anti-La/SSB	Linked to photosensitive rash, dry eyes, and neonatal complications, including congenital heart block.

Classification criteria

No test or single feature is diagnostic of SLE; classification criteria give research cohorts a consistent case definition and are used clinically as a structured guide, not a diagnostic requirement — clinical judgment remains essential, since many individual features (arthritis, fatigue, pericarditis) are common in other conditions.^[2] The 2019 EULAR/ACR classification criteria require a positive ANA (titer of 1:80 or more on HEp-2 cells, or an equivalent positive test) at least once as an obligatory entry criterion. If met, points are summed across 7 clinical and 3 immunologic domains — only the single highest-weighted item within each domain counts toward the total — and a score of 10 or more, with at least 1 clinical criterion present, classifies the patient as having SLE.^[2]

Criterion	Weight
Constitutional — Fever	2
Hematologic — Leukopenia	3
Hematologic — Thrombocytopenia	4
Hematologic — Autoimmune hemolysis	4
Neuropsychiatric — Delirium	2
Neuropsychiatric — Psychosis	3
Neuropsychiatric — Seizure	5
Mucocutaneous — Non-scarring alopecia	2
Mucocutaneous — Oral ulcers	2
Mucocutaneous — Subacute cutaneous or discoid lupus	4
Mucocutaneous — Acute cutaneous lupus	6
Serosal — Pleural or pericardial effusion	5
Serosal — Acute pericarditis	6
Musculoskeletal — Joint involvement (synovitis in ≥2 joints, or tenderness in ≥2 joints plus ≥30 minutes of morning stiffness)	6
Renal — Proteinuria >0.5 g/24h	4
Renal — Biopsy-confirmed Class II or V lupus nephritis	8
Renal — Biopsy-confirmed Class III or IV lupus nephritis	10
Antiphospholipid antibodies — Anticardiolipin, anti-beta-2-glycoprotein I, or lupus anticoagulant	2
Complement proteins — Low C3 or low C4	3
Complement proteins — Low C3 and low C4	4
SLE-specific antibodies — Anti-dsDNA or anti-Smith	6

This weighted, domain-capped scoring structure — where only the single highest-weighted criterion in each domain counts — is not a simple flat point-sum, so it is presented here as a teaching table rather than an interactive calculator; use the full published criteria or a validated tool for an actual classification decision.^[2]

Treatment Targets

Achieve and maintain remission, or the lowest achievable disease activity, across every involved organ system.
Prevent flares and prevent accrual of permanent organ damage.
Minimize cumulative corticosteroid exposure — target prednisone under 5 mg/day (or off corticosteroids entirely) for maintenance, using corticosteroid-sparing agents to get there.
Prevent, screen for, and treat the comorbidities disproportionately common in SLE — cardiovascular disease, infection, and osteoporosis.
Support safe, planned pregnancy and preserve fertility when relevant to the patient.
Improve long-term survival and quality of life.

Choose Initial Treatment

Direct treatment rule

Every patient, 1st line start hydroxychloroquine as background therapy regardless of organ involvement or severity, unless there is a genuine contraindication (e.g., established retinopathy, true hypersensitivity) — this is not reserved for mild disease.^[1]

Non-organ-threatening mucocutaneous or musculoskeletal flare add a short course of low-dose corticosteroid on top of hydroxychloroquine (or a topical/intralesional corticosteroid for isolated skin disease), tapering as soon as the flare is controlled.

Organ-threatening disease — active lupus nephritis, CNS lupus, severe hematologic involvement, or vasculitis — start high-dose corticosteroid (oral or IV pulse) together with an induction immunosuppressant chosen by organ and severity immediately; do not trial a lower-intensity regimen first in organ-threatening disease.^[3]

Steroid-dependent disease — persistent activity despite hydroxychloroquine and corticosteroid, or inability to taper prednisone toward the maintenance target — add a corticosteroid-sparing agent selected by the dominant manifestation (methotrexate for refractory arthritis/skin/serositis; azathioprine or mycophenolate for broader disease control) specifically to enable the corticosteroid taper.

Refractory or severe disease despite an adequate trial of a first corticosteroid-sparing agent — add belimumab or anifrolumab matched to the clinical indication, or refer for cyclophosphamide or rituximab under specialist direction for severe refractory cases.

Non-Pharmacologic Treatment

Patient education is foundational — most therapy decisions depend on the patient understanding why adherence (especially to hydroxychloroquine) matters even when feeling well.
Sun protection: physical measures (protective clothing, a wide-brimmed hat) plus a broad-spectrum sunscreen SPF 30 or higher, applied daily — ultraviolet exposure triggers both cutaneous and systemic flares.
Smoking cessation — reduces the already elevated cardiovascular risk in SLE and improves the effectiveness of antimalarial therapy.
Heart-healthy diet and regular exercise as tolerated.
Confirm immunizations are up to date, using inactivated vaccines, before starting or escalating immunosuppression; avoid live vaccines once a patient is significantly immunosuppressed.
Adequate calcium and vitamin D intake plus weight-bearing exercise to offset the osteoporosis risk from sun avoidance and corticosteroid exposure.
Discuss contraception and family planning at every visit with a reproductive-age patient (see Special Populations).
Cervical cancer screening per standard guidance in sexually active patients under 69 years of age.

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Hydroxychloroquine Preferred	Background therapy, essentially all patients	200-400 mg PO daily; do not exceed 5 mg/kg/day actual body weight	GI upset, rash, rare dose- and duration-related retinal toxicity	Continue indefinitely in stable disease — stopping triggers flares. Requires scheduled ophthalmologic screening (see Monitoring).
Prednisone (low-moderate dose) Preferred	Flare control on top of hydroxychloroquine	Low: up to 15 mg/day PO. Moderate: 0.5-1 mg/kg/day PO	Hyperglycemia, weight gain, mood change, osteoporosis	Taper to the lowest effective dose as soon as the flare is controlled; target under 5 mg/day for maintenance.
Methylprednisolone (IV pulse) Special situation	Organ-threatening disease, urgent control	500-1000 mg IV daily for 3 doses	Hyperglycemia, mood change, infection risk	Used to gain rapid control before or alongside starting an induction immunosuppressant.
Mycophenolate mofetil Preferred	Induction/maintenance, organ-threatening disease including lupus nephritis	Induction: 2000-3000 mg/day PO. Maintenance: 1000-2000 mg/day PO	Cytopenias, GI upset, infection risk	Preferred over cyclophosphamide when fertility preservation matters. Teratogenic — confirm contraception.
Cyclophosphamide Special situation	Severe organ-threatening induction (nephritis, CNS, vasculitis)	Low-dose: 500 mg IV every 2 weeks for 6 doses. High-dose: 500-1000 mg/m² IV monthly for 6 doses	Cytopenias, infertility, hemorrhagic cystitis, infection	The low-dose regimen has comparable efficacy with less toxicity in most patients; high-dose carries a real permanent-infertility risk.
Azathioprine Alternative	Maintenance after induction; pregnancy-compatible option	2 mg/kg/day PO	Cytopenias, hepatotoxicity, GI upset	Preferred maintenance agent when pregnancy is planned or ongoing.
Methotrexate Alternative	Steroid-sparing for refractory arthritis, skin, or serositis	10-25 mg PO or SC weekly, with folic acid	Hepatotoxicity, cytopenias, GI upset	Contraindicated in pregnancy — confirm contraception and stop at least 3 months before conception.
Belimumab Preferred	Add-on for active autoantibody-positive SLE, including lupus nephritis	IV: 10 mg/kg Q2 weeks x3, then Q4 weeks. SC: 400 mg (two 200 mg injections) weekly x4, then 200 mg weekly	Infusion/injection reactions, infection, depression	Add-on to standard therapy, never monotherapy. Avoid live vaccines within 30 days of starting.
Anifrolumab Alternative	Add-on for moderate-severe SLE, especially skin/joint-predominant	300 mg IV over 30 minutes every 4 weeks	Infusion reactions, herpes zoster, respiratory infection	Give herpes zoster vaccination before starting given the increased zoster risk.
Voclosporin Special situation	Add-on for active lupus nephritis, with mycophenolate and a corticosteroid	23.7 mg PO BID; dose-reduced for declining renal function or hepatic impairment	Hypertension, nephrotoxicity, QT prolongation	Never used as monotherapy for lupus nephritis — always add-on to the mycophenolate/corticosteroid background.
Low-dose ASA Special situation	Antiphospholipid antibody-positive patients and pregnancy	81 mg PO daily	GI upset, bleeding	Started for preeclampsia prevention around 12 weeks' gestation in every SLE pregnancy, continued to term.

Special Populations

Pregnancy: aim for about 6 months of disease quiescence before conception when possible — active disease at conception predicts high disease activity in pregnancy and worse outcomes (renal flare, preeclampsia, preterm delivery, low birth weight, pregnancy loss).^[4] Assess disease activity, particularly renal function, at baseline and at least once per trimester. Continue hydroxychloroquine throughout pregnancy — it reduces flares and lowers the risk of neonatal complications, including congenital heart block, in anti-Ro/SSA- or anti-La/SSB-positive patients.^[4] Give low-dose ASA (81 mg/day) starting around 12 weeks' gestation through term for preeclampsia prevention in every SLE pregnancy. Keep prednisone at the lowest effective dose — higher doses raise the risk of hypertension, preeclampsia, and prematurity — and do not taper the dose until 3 months postpartum. Dexamethasone and other fluorinated corticosteroids cross the placenta and are avoided except when specifically treating fetal complications of neonatal lupus (e.g., emerging heart block) under specialist direction. Restrict NSAIDs to the first and second trimester; avoid entirely after 32 weeks given the risk of premature ductus arteriosus closure, and use only short-term with amniotic fluid monitoring between 20 and 32 weeks given a signal for fetal oligohydramnios. Azathioprine (2 mg/kg/day or less) is considered safe throughout pregnancy and is the preferred maintenance immunosuppressant when pregnancy is planned or ongoing.^[4]

Medications requiring a switch before conception

Methotrexate — stop at least 3 months before attempting conception; switch to hydroxychloroquine and/or azathioprine.
Mycophenolate mofetil/sodium — stop at least 6 weeks before attempting conception; switch to azathioprine, observing disease activity for at least 6 months before conception where possible.
Cyclophosphamide — teratogenic; also carries a real fertility-preservation concern independent of the pregnancy-timing issue (see below).
Leflunomide — teratogenic; if pregnancy is desired, either wait 2 years after stopping, or complete a washout (cholestyramine 8 g PO three times daily, or activated charcoal 50 g PO 4 times daily, for 11 days, not necessarily consecutive) followed by 2 plasma level checks at least 14 days apart confirming a concentration under 0.02 mg/L before conceiving. Cholestyramine and activated charcoal both reduce combined oral contraceptive absorption — use a non-hormonal contraceptive method during the washout.

Fertility preservation

Cyclophosphamide can cause permanent infertility depending on cumulative dose and patient age; discuss fertility preservation (GnRH agonist co-therapy, oocyte or embryo cryopreservation) before starting cyclophosphamide in a patient who may want a future pregnancy.

Breastfeeding: hydroxychloroquine, azathioprine (2 mg/kg or less), and most NSAIDs (ibuprofen preferred for its short half-life) are compatible with breastfeeding. Prednisone doses under 20 mg/day are generally considered compatible; higher doses appear in breast milk in amounts that may affect the infant. Methotrexate, mycophenolate, and cyclophosphamide are not compatible with breastfeeding.

Antiphospholipid syndrome overlap

Antiphospholipid antibodies (anticardiolipin, lupus anticoagulant, anti-beta-2-glycoprotein I) occur in a substantial minority of SLE patients and define antiphospholipid syndrome (APS) when accompanied by a qualifying thrombotic or obstetric event, confirmed on 2 occasions at least 12 weeks apart.^[5] Management is risk- and event-stratified, not uniform:

Antiphospholipid antibody-positive, no prior thrombotic or obstetric event: primary thromboprophylaxis with low-dose ASA, particularly with a high-risk antibody profile (triple positivity, lupus anticoagulant, or persistently high titers); continue hydroxychloroquine, which itself carries antithrombotic benefit.^[5]
First venous thrombotic event: indefinite vitamin K antagonist (warfarin), target INR 2-3. Direct oral anticoagulants are not recommended, particularly with triple-positive or arterial/recurrent disease, given evidence of a higher recurrence rate compared with warfarin.^[5]
Arterial thrombotic event: indefinite vitamin K antagonist, target INR 2-3 (some specialists use a higher target or add low-dose ASA in a high-risk profile) — specialist-directed.^[5]
Obstetric APS (recurrent early pregnancy loss, a loss at or after 10 weeks, or preterm delivery for placental insufficiency): low-dose ASA plus prophylactic-dose heparin (unfractionated or low-molecular-weight) throughout pregnancy — the combination improves live birth rate and reduces preeclampsia risk compared with ASA alone.^[5]
Catastrophic APS (see Red Flags & Refer) — a medical emergency requiring combination anticoagulation, high-dose corticosteroid, and specialist-directed adjunctive therapy (e.g., plasma exchange or IVIG).

Pediatric and adolescent-onset SLE

Childhood-onset SLE tends to be more severe, with a higher rate of lupus nephritis, and needs pediatric rheumatology involvement; hydroxychloroquine dosing follows the same actual-body-weight ceiling (5 mg/kg/day or less).

Renal impairment

Dose-adjust azathioprine, mycophenolate, and methotrexate for reduced renal function; avoid or minimize NSAID use given additional nephrotoxicity risk on top of lupus nephritis. Voclosporin has a specific eGFR-triggered dose-reduction protocol (see Drug Tables).

Older adults

Increased vigilance for infection and malignancy is needed with chronic immunosuppression, and corticosteroid-related fracture risk is higher — reinforce bone-health measures (see Monitoring & Follow-Up).

Monitoring & Follow-Up

Disease activity and cumulative organ damage are assessed by a specialist using structured composite instruments (e.g., SLEDAI for activity, the SLICC/ACR Damage Index for damage) — these are specialist-administered composite tools requiring detailed exam and laboratory findings, not a simple point-sum a pharmacist calculates at point of care, so no self-service calculator is provided here; pharmacists should instead track the individual lab trends and clinical findings below and flag concerning changes to the treating specialist.

Follow-up interval: every 1-3 months for active disease; every 6-12 months for mild or inactive disease.^[1]
At each visit on immunosuppression: CBC, creatinine, urinalysis (with a urine protein-to-creatinine ratio when indicated), and agent-specific labs (see Drug Tables for the exact monitoring schedule by drug).
Trend anti-dsDNA and C3/C4 complement over time — rising anti-dsDNA with falling complement can herald a flare, particularly renal.
Cardiovascular risk factor screening and management at every visit — blood pressure, lipids, glucose, weight, and smoking status — given the markedly elevated cardiovascular risk in SLE.
Bone health: baseline and periodic bone density (DXA) in patients on chronic corticosteroids; ensure adequate calcium (1200 mg/day elemental, from all sources) and vitamin D (at least 1000 units/day); start a bisphosphonate for corticosteroid-induced osteoporosis prevention in a patient taking prednisone 7.5 mg/day or more for 6 months or longer who also has a hip/spine Z-score under -3 or more than 10% per year bone loss, or in anyone taking 30 mg/day or more with a cumulative dose over 5 g in 1 year.
Ophthalmologic screening for hydroxychloroquine retinopathy: a baseline exam at or soon after starting, then annual screening (OCT plus wide-field autofluorescence as the primary tests, with visual field or ERG as confirmatory) starting after 5 years of use in an average-risk patient, or from the outset in a high-risk patient (dose over 5 mg/kg/day actual body weight, treatment beyond 5 years, renal impairment, concurrent tamoxifen, older age at initiation, or pre-existing retinal disease).^[6]
Screen for osteonecrosis symptoms (joint pain out of proportion to known disease activity, especially hip or knee) in a patient with substantial cumulative glucocorticoid exposure; image if suspected.
Review immunization status at least annually and before any escalation of immunosuppression.
Cervical cancer screening per standard guidance in sexually active patients under 69 years of age.

Treatment Failure / Next Step

Confirm adherence to hydroxychloroquine and the current regimen before escalating therapy — nonadherence is a common cause of apparent treatment failure, and abruptly stopping hydroxychloroquine can itself trigger a flare.
Distinguish a true flare from infection or another mimicking process before intensifying immunosuppression — treating an infection as a flare can be dangerous, and vice versa.
Confirm the corticosteroid dose and taper pace matched the severity and organ involved — under-dosing organ-threatening disease is a common, preventable cause of apparent treatment failure.
If flaring on hydroxychloroquine plus corticosteroid alone, or unable to taper prednisone toward the maintenance target, add a corticosteroid-sparing immunosuppressant matched to the dominant manifestation.
If flaring despite an adequate trial of a first corticosteroid-sparing agent, or in organ-threatening disease not responding to standard induction, escalate to a biologic (belimumab or anifrolumab, matched to indication) or refer for cyclophosphamide or rituximab under specialist direction.
For lupus nephritis specifically not achieving response at 3-6 months of induction therapy, refer promptly for repeat renal biopsy and specialist reassessment rather than prolonging an ineffective regimen — the histologic class can change over time, and the treatment plan needs to match the current biopsy findings.^[3]

Common Errors to Avoid

Stopping hydroxychloroquine in a patient with stable disease — withdrawal is a well-documented flare trigger; continue indefinitely unless there is a genuine contraindication.
Exceeding the hydroxychloroquine 5 mg/kg actual-body-weight ceiling, or missing scheduled ophthalmologic screening.
Treating lupus nephritis as "quiet" because the patient feels well — renal disease is frequently clinically silent and must be actively screened for with labs, not inferred from symptoms.
Under-treating organ-threatening disease with a low-dose corticosteroid alone instead of the indicated high-dose corticosteroid plus induction immunosuppressant.
Giving a live vaccine to a patient on significant immunosuppression.
Missing NSAID-induced aseptic meningitis as a cause of headache or meningismus in an SLE patient — a real, drug-specific mimicker of CNS lupus.
Attributing every new symptom automatically to "a flare" without excluding infection or an unrelated cause first, especially in a febrile immunosuppressed patient.
Using sulfamethoxazole/trimethoprim without caution — it can itself trigger a photosensitive rash or flare, though it remains indicated as Pneumocystis jirovecii pneumonia prophylaxis during potent immunosuppression.
Continuing methotrexate or mycophenolate too long in a patient planning conception, instead of switching to a pregnancy-compatible agent with adequate lead time.
Choosing a direct oral anticoagulant instead of warfarin for a patient with thrombotic antiphospholipid syndrome.
Missing a bone-health plan (calcium, vitamin D, bisphosphonate when indicated) in a patient on long-term moderate-to-high-dose corticosteroids.

Clinical Decision Algorithm

Initial treatment tier by organ involvement

Confirmed or strongly suspected SLE (clinical features + autoantibodies, ± biopsy)

Start hydroxychloroquine (200-400 mg/day, max 5 mg/kg/day actual body weight) as background therapy in every patient without a contraindication

Mucocutaneous/musculoskeletal disease only, no organ threat

Add a short, low-dose prednisone course for flares; taper once controlled

Add a corticosteroid-sparing agent (methotrexate or azathioprine) if steroid-dependent

Organ-threatening disease: renal, CNS, severe hematologic, or vasculitis

High-dose corticosteroid (oral prednisone or IV methylprednisolone pulse) plus an induction immunosuppressant started immediately — proceed to the lupus nephritis pathway below if renal

Lupus nephritis induction and maintenance

Biopsy-confirmed active proliferative lupus nephritis (Class III/IV, ± V)

High-dose corticosteroid (oral prednisone or IV methylprednisolone pulse) plus choice of induction regimen

Mycophenolate-based

Mycophenolate mofetil 2000-3000 mg/day + prednisone, ± add-on belimumab or a calcineurin inhibitor (voclosporin or tacrolimus) per current combination-therapy guidance

Cyclophosphamide-based

Low-dose IV cyclophosphamide (Euro-Lupus regimen: 500 mg every 2 weeks x6 doses) + prednisone

Fertility preservation a priority

Favor mycophenolate over cyclophosphamide; discuss fertility preservation options if cyclophosphamide is still required

Reassess response at 3-6 months

Responding

Transition to maintenance: mycophenolate or azathioprine; taper prednisone toward 5 mg/day or less

Not responding

Repeat renal biopsy; specialist reassessment of the regimen

Antiphospholipid antibody-positive SLE

Antiphospholipid antibodies confirmed on 2 occasions at least 12 weeks apart

No prior thrombotic/obstetric event

Low-dose ASA ± hydroxychloroquine (primary thromboprophylaxis)

Prior venous or arterial thrombosis

Indefinite warfarin, target INR 2-3 — not a direct oral anticoagulant

Obstetric APS in a current pregnancy

Low-dose ASA plus prophylactic-dose heparin throughout pregnancy

Rapid multi-organ thrombosis over days = catastrophic APS — emergency hospitalization, combination anticoagulation, high-dose corticosteroid, specialist-directed adjunctive therapy

Drug Tables

How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Antimalarials

The only antimalarial used in SLE — chloroquine carries a higher retinal toxicity risk and is no longer marketed in Canada.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Hydroxychloroquine	Adults: 200-400 mg PO daily Pediatric: Weight-based dosing under specialist direction, following the same 5 mg/kg/day actual-body-weight ceiling	Nausea, cramps, diarrhea, rash, headache, skin hyperpigmentation; rare dose-related retinal toxicity and myopathy	May increase digoxin levels; avoid QT-prolonging agents; concurrent tamoxifen increases retinal toxicity risk; avoid live vaccines during use	May take up to 2 months to see an effect. Continue indefinitely in stable disease. Do not exceed 5 mg/kg/day actual body weight.

Corticosteroids

Route and dose scale with disease severity; combine with a corticosteroid-sparing agent whenever more than a brief course is needed.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Prednisone	Low dose: Up to 15 mg/day PO Moderate dose: 0.5-1 mg/kg/day PO High dose: 1 mg/kg/day PO or more	Acne, skin fragility, striae, GI upset, weight gain, glucose intolerance, mood change, myopathy, glaucoma, cataracts, hypertension, osteoporosis, avascular necrosis, adrenal suppression, increased infection risk	Increased GI ulceration risk with NSAIDs	Consider bisphosphonate prophylaxis for corticosteroid-induced osteoporosis per the criteria in Monitoring & Follow-Up.
Methylprednisolone sodium succinate	IV pulse: 500-1000 mg IV daily for 3 doses	Same profile as prednisone, more pronounced with pulse dosing	Increased GI ulceration risk with NSAIDs	Used for urgent control in organ-threatening disease, alongside starting an induction immunosuppressant.

Conventional immunosuppressants

Drug	Dosage	Adverse effects	Drug interactions	Comments
Azathioprine	Adults: 2 mg/kg/day PO Pregnancy/breastfeeding-compatible dose: 2 mg/kg/day PO or less	Nausea, vomiting, diarrhea, fever, malaise, hepatotoxicity, leukopenia, thrombocytopenia, infection, myalgia	May inhibit the hypoprothrombinemic response to warfarin; allopurinol increases toxicity — reduce azathioprine dose to 25% of usual and monitor closely; increased neutropenia risk with ACE inhibitors	May take up to 3 months to be effective. Monitor CBC weekly for month 1, twice monthly for months 2-3, then monthly. Monitor LFTs and creatinine monthly.
Cyclophosphamide	Low-dose (Euro-Lupus) regimen: 500 mg IV every 2 weeks for 6 doses High-dose regimen: 500-1000 mg/m² IV monthly for 6 doses	Nausea, vomiting, cytopenias, infertility, hemorrhagic cystitis, increased infection susceptibility, malignancy potential	Avoid live vaccines; ensure vaccinations are up to date before starting	Usually combined with oral prednisone, with or without 3 pulses of methylprednisolone. High-dose regimen carries a real permanent-infertility risk — discuss fertility preservation first.
Methotrexate	Adults: 10-25 mg PO or SC weekly, with folic acid 5 mg weekly or 1 mg daily	Nausea, malaise, headache, oral ulcers, alopecia, diarrhea, cytopenias, hepatotoxicity, pneumonitis	Sulfonamides (e.g., sulfamethoxazole/trimethoprim) may decrease methotrexate clearance; alcohol increases hepatotoxicity risk	Increased toxicity risk with lupus nephritis/renal impairment. Give folic acid to reduce GI, hepatic, and mucosal toxicity. Contraindicated in pregnancy.
Leflunomide	Adults: 10-20 mg PO daily	Nausea, diarrhea, anorexia, weight loss, alopecia, rash, hypertension, hepatotoxicity, cytopenias, pulmonary fibrosis	Decreased leflunomide levels with cholestyramine; increased infection risk with live vaccines	Occasionally used for refractory arthritis. Pregnancy is contraindicated while taking this medication — a cholestyramine or activated-charcoal washout is required before conception (see Special Populations).
Mycophenolate mofetil	Induction: 2000-3000 mg/day PO in divided doses, typically for about 6 months Maintenance: 1000-2000 mg/day PO in divided doses	Anemia, leukopenia, thrombocytopenia, hyper/hypotension, edema, hyperglycemia, hypercholesterolemia, hypokalemia, nausea, vomiting, diarrhea, abdominal pain, headache, rash	Antacids, iron, magnesium, and cholestyramine decrease absorption; decreased oral contraceptive efficacy; probenecid increases mycophenolate levels; avoid live vaccines	As efficacious as cyclophosphamide for induction in proliferative lupus nephritis, and preferred when fertility preservation matters. Monitor CBC weekly for month 1, twice monthly for months 2-3, then monthly; monitor LFTs and creatinine monthly.
Mycophenolate sodium	Induction: 1440-2160 mg/day PO in divided doses Maintenance: 720-1440 mg/day PO in divided doses	Same profile as mycophenolate mofetil	Same as mycophenolate mofetil	Enteric-coated formulation; considered likely equivalent in efficacy to mycophenolate mofetil. 720 mg mycophenolate sodium is approximately equivalent to 1000 mg mycophenolate mofetil.

Calcineurin inhibitors

Used for refractory or membranous (Class V) lupus nephritis, or as an add-on to mycophenolate per current combination-therapy guidance; monitor drug levels, blood pressure, renal function, and metabolic parameters closely with all agents in this class.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Cyclosporine	Lupus nephritis: 3-5 mg/kg/day PO in 2 divided doses	Hypertension, hyperlipidemia, tremor, renal dysfunction, nausea, vomiting, abdominal pain, diarrhea, gingival hyperplasia, paresthesia, hypertrichosis, fatigue, hirsutism	CYP3A4/P-glycoprotein/bile salt efflux pump inhibitor — interacts with grapefruit, erythromycin, ketoconazole, rifampin; potential nephrotoxicity with aminoglycosides	May be used for maintenance therapy, combined with low-dose corticosteroid, in lupus nephritis patients intolerant of mycophenolate and azathioprine or in refractory cases. Monitor blood pressure monthly; monitor creatinine, CBC, LFTs, electrolytes, and drug levels.
Tacrolimus	Lupus nephritis: 0.05-0.1 mg/kg/day PO in divided doses, adjusted to trough levels	Hypertension, hyperlipidemia, tremor, renal dysfunction, nausea, vomiting, abdominal pain, diarrhea, paresthesia, fatigue	CYP3A4/P-glycoprotein/bile salt efflux pump inhibitor — interacts with grapefruit, erythromycin, ketoconazole, rifampin; potential nephrotoxicity with aminoglycosides	May be used for maintenance therapy, combined with low-dose corticosteroid, in lupus nephritis patients intolerant of mycophenolate and azathioprine or in refractory cases, and as an add-on to mycophenolate per current combination-therapy guidance. Monitor blood pressure monthly; monitor creatinine, CBC, LFTs, electrolytes, and drug levels.
Voclosporin	Starting dose: 23.7 mg PO BID Renal-function-triggered reduction: Reduce by 7.9 mg (1 capsule) BID per decline in eGFR Hepatic impairment (Child-Pugh A/B): Reduce to 15.8 mg PO BID	Decreased eGFR, hypertension, diarrhea, headache, anemia, QT prolongation, posterior reversible encephalopathy syndrome (rare)	CYP3A4 substrate — avoid strong/moderate CYP3A4 inhibitors and inducers; additive nephrotoxicity with other nephrotoxic drugs; additive QT prolongation with other QT-prolonging drugs	Approved specifically as an add-on to mycophenolate mofetil and a corticosteroid for active lupus nephritis — never monotherapy. Reassess eGFR within 2 weeks of any dose reduction.

Biologics

Drug	Dosage	Adverse effects	Drug interactions	Comments
Belimumab	IV: 10 mg/kg infused over 1 hour every 2 weeks for 3 doses, then every 4 weeks Subcutaneous: 400 mg (two 200 mg injections) once weekly for 4 doses, then 200 mg once weekly	Nausea, diarrhea, fever, anxiety, insomnia, depression, infusion/injection reactions, hypersensitivity	Avoid live vaccines; ensure vaccinations are up to date before starting; not recommended in combination with rituximab	Add-on to standard therapy for mild-to-moderate active autoantibody-positive SLE, including lupus nephritis. Premedicate with acetaminophen and an antihistamine before infusion. Benefit may be delayed by 3-9 months.
Anifrolumab	Adults: 300 mg IV infused over 30 minutes every 4 weeks	Arthralgia, cough, pharyngitis, respiratory tract infection, herpes zoster infection, depression, infusion reactions, hypersensitivity	Avoid live vaccines; ensure vaccinations are up to date before starting	A type 1 interferon receptor antagonist. Give herpes zoster vaccination before starting given the increased zoster risk. Not evaluated in severe active lupus nephritis or CNS lupus.
Rituximab (off-label)	Off-label, refractory disease: 1 g IV x2 doses, 2 weeks apart, with methylprednisolone 100 mg IV premedication	Mild-to-severe infusion reactions (rarely fatal), rare progressive multifocal leukoencephalopathy	Avoid live vaccines; ensure vaccinations are up to date before starting	Not formally approved for SLE — used off-label for severe refractory hematologic involvement or refractory nephritis. Premedicate with acetaminophen and an antihistamine (e.g., cetirizine); monitor for hypersensitivity.

Refractory cutaneous disease

Reserved for cutaneous lupus refractory to hydroxychloroquine and standard immunosuppression, given significant adverse-effect burden.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Thalidomide	Initial: 50-100 mg PO daily Maintenance: Reduced to the minimum effective dose once controlled	Peripheral neuropathy, teratogenicity, sedation, constipation, venous thromboembolism	Additive sedation with CNS depressants	Highly effective for refractory skin disease, but use is tightly restricted to a controlled distribution system given teratogenicity and neuropathy risk.
Lenalidomide	Refractory cutaneous lupus: Individualized under specialist direction — not established as a standard fixed regimen for this indication	Cytopenias, teratogenicity, venous thromboembolism, rash	Additive cytopenia risk with other bone-marrow-suppressive agents	A safer alternative to thalidomide for refractory skin disease, with less neuropathy risk, though still teratogenic and requiring a controlled distribution program.

NSAIDs and antiplatelet therapy

High-dose NSAIDs have been associated with aseptic meningitis in SLE patients specifically, and all NSAIDs carry cardiovascular risk — use the lowest effective dose for the shortest duration.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Ibuprofen	Adults: 400-600 mg PO every 6-8 hours as needed, lowest effective dose	GI upset, GI ulceration/bleeding, cardiovascular risk, rare aseptic meningitis in SLE	Increased bleeding with anticoagulants; reduces antihypertensive efficacy of ACE inhibitors/ARBs/diuretics	For arthralgia, myalgia, or pleuritic/pericardial pain. Preferred NSAID in breastfeeding given its short half-life.
Naproxen	Adults: 250-500 mg PO twice daily	GI upset, GI ulceration/bleeding, cardiovascular risk, rare aseptic meningitis in SLE	Increased bleeding with anticoagulants; reduces antihypertensive efficacy of ACE inhibitors/ARBs/diuretics	Alternative NSAID for arthralgia, myalgia, or pleuritic/pericardial pain.
Acetylsalicylic acid (low-dose)	Adults: 81 mg PO daily	GI upset, bleeding	Additive bleeding risk with anticoagulants and other antiplatelet agents	Used for cardiovascular risk reduction and for preeclampsia/pregnancy-complication prevention in antiphospholipid antibody-positive patients (see Special Populations).

Antiphospholipid syndrome anticoagulation

See Special Populations for the full risk- and event-stratified approach.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Enoxaparin	Pregnancy prophylactic dosing: 40 mg SC daily, adjusted for weight and renal function Treatment dosing: 1 mg/kg SC every 12 hours	Bleeding, injection-site hematoma, rare heparin-induced thrombocytopenia	Additive bleeding risk with other antiplatelet/anticoagulant agents	Preferred low-molecular-weight option for obstetric APS and for bridging.
Heparin (unfractionated)	Bridging/inpatient: Weight-based dosing per institutional protocol	Bleeding, heparin-induced thrombocytopenia	Additive bleeding risk with other antiplatelet/anticoagulant agents	Alternative to enoxaparin, particularly with significant renal impairment or in an inpatient bridging context.
Warfarin	APS thromboprophylaxis: Dose-titrated to target INR 2-3	Bleeding	Numerous drug and dietary vitamin K interactions — requires regular INR monitoring	Indefinite therapy after a confirmed venous or arterial thrombotic event in antiphospholipid syndrome. Direct oral anticoagulants are not recommended in this setting.

Bone health

For prevention and treatment of corticosteroid-induced osteoporosis — see Monitoring & Follow-Up for the specific dose/duration thresholds that trigger bisphosphonate therapy.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Calcium carbonate	Adults: Dosed to reach 1200 mg/day elemental calcium from all sources, in divided doses	Constipation, GI upset	Reduces absorption of several oral drugs (e.g., levothyroxine, tetracyclines, some fluoroquinolones) — separate dosing by at least 2 hours	Target elemental calcium 1200 mg/day total from all dietary and supplemental sources.
Vitamin D3	Adults: At least 1000 units PO daily	Rare hypercalcemia with excessive dosing	None significant at standard doses
Alendronic acid	Corticosteroid-induced osteoporosis prevention/treatment: 70 mg PO once weekly, or 10 mg PO once daily	Esophagitis, GI upset, rare osteonecrosis of the jaw, rare atypical femur fracture	Reduced absorption with calcium, antacids, and other oral medications taken at the same time	Take on an empty stomach with a full glass of water, remaining upright for at least 30 minutes. Avoid in women of childbearing potential planning pregnancy given prolonged skeletal retention.
Denosumab	Alternative bone agent: 60 mg SC every 6 months	Hypocalcemia, rare osteonecrosis of the jaw, rare atypical femur fracture, increased infection risk (immunosuppressed patients)	Additive hypocalcemia risk with other bone-modifying agents	Alternative to a bisphosphonate when oral therapy is not tolerated or contraindicated; use with additional caution given the underlying immunosuppression in SLE.

Infection prophylaxis and vaccination

Evaluate immunization status before starting immunosuppression; use inactivated vaccines and avoid live vaccines (e.g., the live-attenuated zoster or MMR vaccines) once a patient is significantly immunosuppressed.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Sulfamethoxazole/trimethoprim	PJP prophylaxis during potent immunosuppression: 800/160 mg PO 3 times weekly, or per institutional protocol	Photosensitive rash, cytopenias, hyperkalemia — can itself trigger an SLE flare	Increased methotrexate levels; increased hyperkalemia risk with ACE inhibitors/ARBs; potentiates warfarin	Use with caution given the specific risk of inducing a lupus flare or photosensitive rash, but remains indicated for Pneumocystis jirovecii pneumonia prophylaxis in patients on potent immunosuppression.
Influenza vaccine (inactivated)	Annual: 1 dose IM annually	Injection-site soreness, low-grade fever	None significant	Inactivated formulation — safe during immunosuppression; give annually.
Pneumococcal conjugate vaccine	Per current adult immunization schedule: 1 dose IM per current schedule for immunocompromised patients	Injection-site soreness, low-grade fever	None significant	Inactivated formulation — safe during immunosuppression.
Recombinant zoster vaccine	Adults 50 years and older, including immunosuppressed patients: 2 doses IM, 2 to 6 months apart	Injection-site reactions, myalgia, fatigue, headache	None significant	Non-live, recombinant vaccine — the correct choice during or before immunosuppression, unlike the live-attenuated zoster vaccine, which is avoided once a patient is significantly immunosuppressed.

Topical/cutaneous therapy

For isolated cutaneous lupus not requiring systemic escalation.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Topical corticosteroid	Cutaneous lupus/localized rash: Applied per standard topical corticosteroid dosing for the potency and site chosen	Skin atrophy, telangiectasia with prolonged high-potency use	None significant	Potency selected by lesion site and severity; a first-line topical option for localized rashes.
Pimecrolimus	Cutaneous lupus, corticosteroid-sparing alternative: Apply a thin layer to affected skin twice daily	Local burning or stinging at the application site	None significant	A topical calcineurin inhibitor alternative to a topical corticosteroid, avoiding cutaneous atrophy with prolonged use.

References

2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus — Arthritis & Rheumatology, American College of Rheumatology (Sammaritano LR, et al.). Arthritis Rheumatol 2026;78(7):1361-1386
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus — Arthritis & Rheumatology (Aringer M, Costenbader K, Daikh D, et al.). Arthritis Rheumatol 2019;71(9):1400-1412
2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis — Arthritis Care & Research, American College of Rheumatology (Sammaritano LR, et al.). Arthritis Care Res 2025;77(9):1045-1065
2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases — Arthritis & Rheumatology, American College of Rheumatology (Sammaritano LR, et al.). Arthritis Rheumatol 2020;72(4):529-556
EULAR recommendations for the management of antiphospholipid syndrome in adults — Annals of the Rheumatic Diseases, European Alliance of Associations for Rheumatology (Tektonidou MG, Andreoli L, Limper M, et al.). Ann Rheum Dis 2019;78(10):1296-1304
Special AAO Report: Recommendations on Screening for Hydroxychloroquine Retinopathy (2025 Revision) — Ophthalmology, American Academy of Ophthalmology (Marmor MF, Ahn SJ, Ehlers JP, et al.). Ophthalmology 2026;133(4):439-450

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.